Given that the expression and signaling of EBI2 are controlled by multiple IFN‐related regulators (i.e., IFN‐γ, oxysterol, STAT, IFN‐I, and ISGs), it would be exciting to investigate whether detecting the surface expression of EBI2 could predict the therapeutic efficacy of SLE patients who receive Anifrolumab treatment. Here, GPR183 is linked to systemic lupus erythematosus.